| Article

In a study published in the Journal of Clinical Psychology in Medical Settings, 135 people diagnosed with chronic migraine—aged 10 to 17 years, mostly female (79%) and mostly white (89%)—were assessed. Researchers sought to understand “predictors of improvement in headache days and migraine-related...

| Video

Long-term migraine treatment may reduce the number of headaches per month. But it is enough? Botulinum toxin has also helped migraine sufferers. Botox is FDA approved for chronic migraine. Dr. Argoff says when Botox is combined with other medications, migraine occurrence per month is greatly reduced...

| Article

Findings from the 2002 to 2018 National Health Interview Survey for adults aged 25 to 84 are discouraging. Pain prevalence—for headache/migraine, joint, low back, neck, facial/jaw pain—has gone up, with people reporting a 10% increase of pain in at least 1 area. That equals an additional 10.5...

| Article

In a first of its kind clinical—and randomized, double-blind, placebo-controlled—trial, migraine sufferers will be given, via a vaporizer, CBD, THC, CBD and THC, and a placebo for 4 separate migraine attacks. Participants, ages 21 to 65, will self-administer as early as possible at the start of a...

| Article

Earlier this year, it was reported in Cephalalgia that migraine pain could be reduced through the use of intranasal dry air, which cooled nasal passages. The study looked at headache, nausea, sound and photosensitivity. A small study of 51 patients demonstrated a significantly larger lowering of...

| Article

Over 1 billion people in the world live with migraine. In a position statement, Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine, from the International Headache Society (IHS), health technology assessments—"systematic evaluations of the properties...

| Article

The Journal of Headache and Pain reports results of a phase 3 trial of the recently FDA approved eptinezumab—a humanized monoclonal antibody that inhibits calcitonin gene-related peptide—for preventive treatment of migraine in adults. The medication, given in two infusions, provided 24 weeks of...

| Article

INDIANAPOLIS, Oct. 6, 2020 /PRNewswire/ -- Adults who took REYVOW® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 7.2 times greater odds, respectively, of achieving superior pain freedom at 2 hours post treatment compared to those taking placebo in at least 2...

| Podcast

Despite being one of the more frequently noted triggers for migraine, estrogen and its role in the pathology of migraine is still unknown. 

This talk discusses the current understanding of the role of estrogen in the headache experience. We will start by touching on the clinical experience the...

| Article

A cluster of conditions that frequently co-occur, can be local or widespread, and either solely or predominantly affect women are referred to as chronic overlapping pain conditions. They include:

  • Endometriosis
  • Fibromyalgia
  • Painful bladder syndrome
  • Irritable bowel syndrome
  • Chronic low back...

Subscribe to migraine

Sign-Up